28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
This study demonstrates that patients with dementia who suffer a hip fracture can benefit from multidisciplinary geriatric assessment and rehabilitation and should not be excluded from rehabilitation programs. 1 key finding →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
Forty-two case-control, cohort, and randomized trials were identified and included in the review. 3 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
Despite the increased interest in palliative care for patients with dementia there is currently little evidence on which to base such an approach. 1 key finding →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
Successful strategies from other disciplines could be considered by palliative care researchers. 1 key finding →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Pharmacologic treatments for Alzheimer's disease include the cholinesterase inhibitors donepezil, galantamine, and rivastigmine. 3 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713; Exelon, in patients with mild to moderately severe Alzheimer's disease was evaluated in a 26-week open-label extension of a 26-week, double-blind, placebo-controlled study. 1 key finding →
Design: open-label trial Evidence: low
Full summary, score breakdown and related studies → Original source
The COMCID trial will identify the therapeutic potential of cilostazol. 2 key findings →
Design: cohort study Evidence: high
Full summary, score breakdown and related studies → Original source
Donanemab treatment significantly slowed clinical progression at 76w and had a safety profile consistent with earlier studies. 5 key findings →
Participants: 1,182 Evidence: high
Full summary, score breakdown and related studies → Original source
Traumatic brain injury (TBI) is one of the leading causes of injury-related death. 2 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Benefit continued to accrue with ongoing lecanemab treatment through 36 months. 5 key findings →
Design: phase-3-trial Evidence: early
Full summary, score breakdown and related studies → Original source Free full text
Donanemab, a monoclonal antibody targeting the insoluble form of β-amyloid found in plaques, significantly slows cognitive and functional decline of AD in participants with mild cognitive impairment (MCI) or mild AD-related dementia. 4 key findings →
Design: phase-3-trial Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Obicetrapib significantly slowed AD biomarker progression over 12 months in participants with ASCVD, with the greatest effects in ApoE4 carriers. 5 key findings →
Design: clinical trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
These findings suggest a benefit of MI plus omega 3 in positive blood amyloid subjects. 4 key findings →
Participants: 483 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Risk information for Alzheimer disease (AD) may be communicated through susceptibility gene disclosure, even though this is not currently in clinical use. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
This study shows significant therapeutic effects of trazodone 50 mg in community-dwelling AD patients with SD. 3 key findings →
Participants: 15 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Nutrition is a modifiable factor potentially related to aging. 3 key findings →
Design: randomized controlled trial Participants: 661 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Apathy is a common behavioral symptom of Alzheimer's disease (AD), being present in up to 70% of patients. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer is a disease leading to various neuropsychiatric behavioral disorders, and the most common symptom observed during the prognosis of Alzheimer's disease is dysmnesia. 1 key finding →
Participants: 60 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Study objectives We investigated the effectiveness of a lighting intervention tailored to maximally affect the circadian system as a nonpharmacological therapy for treating problems with sleep, mood, and behavior in persons with Alzheimer disease and related dementias (ADRD). 3 key findings →
Participants: 46 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Treatment with celecoxib or naproxen did not improve depressive symptoms over time compared with placebo. 5 key findings →
Design: longitudinal study Participants: 2,528 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The expected outcome is to ensure the continuity of care from clinical practice to the patient's home, enabling also cost effectiveness and the empowerment of patient and caregiver in the care process, positively impacting on their quality of life. 1 key finding →
Design: randomized controlled trial Participants: 30 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Naproxen may attenuate cognitive decline in slow decliners while accelerating decline in fast decliners. 2 key findings →
Participants: 2,388 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Enrollment began in March 2001 and ended in December 2004 when treatments were suspended because of concerns regarding cardiovascular safety of the treatments. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Consistent with trials evaluating other cholinesterase inhibitors, rivastigmine did not provide consistent efficacy in probable VaD. 3 key findings →
Participants: 710 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Advances in genetic research have provided a basis for susceptibility testing for Alzheimer disease (AD). 2 key findings →
Design: randomized controlled trial Participants: 160 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
10 of the 1,875 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →